BeyondMold

CLINICAL PRIMER

CDR / ISRMT PHENOTYPE SERIES · NO. C

The Worn-out Defender

Phenotype C · Worn-out Defender

Reconstituting an exhausted immune system while rebuilding the engine — thymic and immune-modulating peptides, plant sterols, antiviral support, and cofactor repletion, run concurrently.

Andrew Heyman, MD, MHSA

Integrative & Metabolic Medicine · Founder, Beyond Mold

ORIENTATION · HOW TO READ THIS PRIMER

Rebuilding the engine and the defense together

This is the Phenotype C companion to the Beyond Mold phenotype series. It assumes the CDR/ISRmt model and the four-phenotype classification, and that the staging baseline has been run. Its job is to lay out the agents that **reconstitute an exhausted immune system while rebuilding the mitochondrial engine** — because in this phenotype the two failures are co-primary.

Each agent is presented as mechanism, dosing, cautions, and where it fits, with a conservative evidence grade, grouped by lever.

THE CARDINAL RULE OF PHENOTYPE C

Treat the engine and the immune system at the same time. ISRmt impairs the immune reconstitution that would otherwise clear viral reactivation, while viral reactivation perpetuates the ISRmt loop — address one without the other and the result is the characteristic *partial response, then plateau*. At the same time, **do not crudely "boost"** a dysregulated immune system: the goal is re-balancing and retraining (Th1 support, T-reg normalization, NK restoration), not indiscriminate stimulation. Manage viral reactivation and replete the cofactors viruses deplete.

01 · THE PHENOTYPE

What CDR2-Immune actually is

Phenotype C shares the CDR2/ISRmt substrate of Phenotype B but adds a co-primary **immune exhaustion**. Three processes compound: ISRmt is active (GDF15/FGF21 elevated); chronic herpesvirus reactivation (EBV, HHV-6, sometimes CMV), enabled by CDR2 immune suppression, sustains CDR1 signaling through viral PAMPs; and the sustained activation needed to contain those reactivations progressively **exhausts T-cell and NK populations** (CD3/CD4/NK depletion).

Viral neurotropism adds a neurological dimension: EBV/HHV-6 activate microglia and the IDO pathway, shunting tryptophan toward quinolinic acid and producing a *biological*, antidepressant-refractory anhedonia and dysphoria. Herpesviruses also deplete pyridoxal-5-phosphate (active B6), compounding one-carbon demand. The gestalt is **vulnerability**: all of Phenotype B, plus chronic sore throat and tender nodes, night sweats, neuropathic pain, disproportionate illness severity, and a stepwise recovery that jumps then slips with viral flares.

Laboratory signature

Domain	Phenotype C pattern
GDF15 / FGF21	Markedly elevated — ISRmt still primary (the shared CDR2 substrate).
CD3 / CD4 / NK	Depleted across lineages (CD3<800, CD4<500, NK<100/μL) — the defining immune-exhaustion signature.
Viral reactivation	EBV / HHV-6 (± CMV) serologies/PCR consistent with reactivation; night sweats, sore throat.
B6 / PLP	Functionally low — viral PLP depletion; one-carbon strain.
VIP / α-MSH	Low; if critically depleted with collapsed HRV after immune recovery, re-phenotype to D.
HRV	Reduced (compound metabolic + infectious suppression).

02 · STRATEGY

The logic of reconstituting the defense

Phenotype C opens to four reinforcing levers, run *concurrently* rather than sequentially:

- **Reconstitute & retrain immunity** — restore T-cell/NK function and Th1 balance with immune peptides and modulators (not blanket stimulation).
- **Contain viral reactivation** — antiviral support (Rx and natural) to lift the persistent CDR1 viral driver.
- **Rebuild the engine** — run the Phenotype B mitochondrial stack in parallel; neither system recovers alone.
- **Replete what viruses deplete & lower the load** — B6/one-carbon repletion, redox support, and the autonomic/coping arm for the IDO-driven neuropsychiatric residue.

03 · PREREQUISITES

The gate you must earn

Entry conditions for Phenotype C treatment

- **CDR1 environmental drivers controlled** — exposure removed; the remaining CDR1 driver is viral, not environmental.
- **Immune exhaustion confirmed** — CD3/CD4/NK depletion documented, distinguishing C from B.
- **Viral reactivation characterized** — EBV/HHV-6 (± CMV) status established to guide antiviral support.
- **Pacing established** — the shared PEM substrate is respected.

04 · LEVER 1

Reconstitute & retrain immunity

Thymosin α-1 (TA1) PEPTIDE · IMMUNE RETRAINING

Mechanism. A thymic peptide that restores and re-balances adaptive immunity: it promotes T-cell maturation and Th1 polarization, enhances NK and cytotoxic-T function and dendritic-cell signaling, and helps correct the dysregulated immune set-point — the most direct lever on the exhaustion that defines C.

Dosing. ~1.6 mg SubQ twice weekly, typically over 12–16 weeks; clinician-directed, compounded.

Cautions. Generally well tolerated (injection-site reactions); theoretical caution in autoimmunity and organ-transplant immunosuppression; off-label/compounded.

Where it fits. The keystone immune-reconstitution agent; begin early and run alongside the mitochondrial stack. Evidence: C

Low-dose naltrexone (LDN) RX · IMMUNE MODULATION / MICROGLIA

Mechanism. Beyond TLR4/microglial quieting, low-dose naltrexone transiently blocks the opioid-growth-factor axis, producing a rebound that modulates lymphocyte regulation and helps normalize a dysregulated immune response — immune re-balancing plus neuroinflammation control in one agent.

Dosing. Start 1.5 mg qHS; titrate to 3–4.5 mg qHS.

Cautions. Vivid dreams/early sleep disturbance; contraindicated with opioid agonists.

Where it fits. A low-risk immune-modulating background; pairs naturally with TA1. Evidence: B

Plant sterols & sterolins (β-sitosterol : sitosterolin) NATURAL · TH1/TH2 BALANCE

Mechanism. The 100:1 β-sitosterol/β-sitosterolin combination (e.g., Moducare) modulates rather than merely stimulates immunity — supporting Th1 activity and T-cell/NK function while damping over-reactive Th2 and cortisol/DHEA stress effects. Long used in tuberculosis, HIV, and stress-related immune suppression.

Dosing. Typically 20 mg sterol / 0.2 mg sterolin per capsule, 1 capsule 3×/day on an empty stomach.

Cautions. Well tolerated; take away from fiber/fats that impair absorption; theoretical autoimmunity caution.

Where it fits. A foundational natural immune-modulator alongside TA1. Evidence: C

AHCC & beta-glucans NATURAL · NK / INNATE TRAINING

Mechanism. Active hexose correlated compound (shiitake mycelium) and 1,3/1,6 beta-glucans support NK-cell activity and train innate immunity, with antiviral signal in herpesvirus and related contexts.

Dosing. AHCC 1–3 g/day; beta-glucan 250–500 mg/day.

Cautions. Well tolerated; mild GI; theoretical autoimmunity caution.

Where it fits. Innate-immune support layered onto the adaptive reconstitution. Evidence: C

05 · LEVER 2

Contain viral reactivation

Antiviral therapy (clinician-prescribed) RX · HERPESVIRUS SUPPRESSION

Mechanism. Where EBV/HHV-6/CMV reactivation is a confirmed driver, suppressive antivirals (e.g., valacyclovir; valganciclovir for HHV-6/CMV in selected cases) lift the persistent viral CDR1 input that perpetuates the ISRmt loop.

Dosing. Per standard antiviral protocols; specialist-directed with monitoring.

Cautions. Renal dosing and hydration (valacyclovir); marrow suppression and strict monitoring (valganciclovir); confirm indication before use.

Where it fits. A targeted move against the viral driver, paced with binder/Herxheimer management. Evidence: B

Lactoferrin, monolaurin & astragalus NATURAL · ANTIVIRAL SUPPORT

Mechanism. Lactoferrin (antiviral/antimicrobial, NK support, iron handling), monolaurin (disrupts enveloped viruses including herpesviruses), and astragalus (antiviral, T-cell support) provide gentler, layerable antiviral pressure.

Dosing. Lactoferrin 200–400 mg/day; monolaurin 600–1800 mg/day; astragalus per product.

Cautions. Generally well tolerated; monolaurin GI; astragalus theoretical autoimmunity/immunosuppressant caution.

Where it fits. Natural adjuncts to antiviral suppression; useful where Rx antivirals are not indicated or tolerated. Evidence: C

Medicinal mushrooms NATURAL · IMMUNE MODULATION

Mechanism. Reishi, cordyceps, and turkey-tail (PSK/PSP) extracts modulate immunity and add antiviral and adaptogenic effects, with cordyceps also supporting bioenergetics.

Dosing. Per standardized product; often combined.

Cautions. Well tolerated; mild GI; theoretical autoimmunity caution.

Where it fits. Broad immune-modulating background. Evidence: C

06 · LEVERS 3 & 4

Rebuild the engine & replete the cofactors

Because C shares the CDR2 substrate, **run the Phenotype B mitochondrial stack concurrently** — CoQ10/ubiquinol, NAD+ precursors, carnitine, riboflavin/B-complex, magnesium, D-ribose, creatine, and NAC — rather than waiting for immune recovery. Neither system restores in isolation. In addition, replete what the viral process specifically drains:

B6 (P5P) & one-carbon support NATURAL · COFACTOR REPLETION

Mechanism. Herpesviruses deplete pyridoxal-5-phosphate as an immune-evasion strategy, impairing interferon synthesis and lymphocyte proliferation and compounding ISRmt-driven one-carbon (SHMT2) demand. Repletion restores a doubly depleted pool.

Dosing. P5P (active B6) at repletion doses; methylfolate and methyl-B12 to support one-carbon flux.

Cautions. High chronic B6 (especially pyridoxine HCl) risks neuropathy — use P5P and monitor.

Where it fits. Targeted repletion of the cofactors the viral process drains. Evidence: C

Vitamin D & zinc NATURAL · ANTIVIRAL IMMUNITY

Mechanism. Vitamin D supports antiviral and regulatory immune function; zinc supports antiviral defense and lymphocyte function and is commonly low.

Dosing. Vitamin D to a target of ~40–60 ng/mL (often 2,000–5,000 IU/day); zinc 15–30 mg/day with copper balance.

Cautions. Monitor 25-OH-D and calcium; zinc can deplete copper at higher chronic doses.

Where it fits. Foundational immune cofactors beneath the specific agents. Evidence: B

Lower the load & address the IDO residue

The IDO-driven anhedonia of C is biological, not a motivational failure, and antidepressants are often ineffective. Lower allostatic load with the autonomic and coping arm (HRV/resonance breathing, vagal toning, the daily send-safety rhythm, defusion and self-compassion from the resilience primer), which also restrains the neuroinflammatory tone. Thymosin β-4 (TB-500) is sometimes added for tissue repair and immune modulation in the rebuild — restoration-phase, evidence D.

07 · THE ROADMAP

A sequenced approach

Stage	Do	Exit gate
0 · Earn it	Confirm environmental CDR1 controlled; document immune exhaustion and characterize viral reactivation; establish pacing.	Exposure clear; CD3/CD4/NK depletion confirmed; viral status known.
1 · Dual foundation	Begin TA1 + LDN + plant sterols, and the Phenotype B mitochondrial stack, together. Replete B6/one-carbon, vitamin D, zinc.	Tolerating both arms; no flare from over-stimulation.
2 · Contain virus	Add antiviral support (Rx where indicated; lactoferrin/monolaurin/astragalus otherwise), paced for Herxheimer reactions.	Viral-flare frequency falling; sore throat/night sweats settling.
3 · Reconstitute	Continue immune retraining and engine rebuild; add mushrooms/AHCC; support the IDO residue with the autonomic/coping arm.	CD3/CD4/NK recovering; GDF15 trending down; stepwise gains stabilizing.
4 · Re-phenotype	Reassess at ~12 weeks. If GDF15 stabilizes and immune counts recover but VIP/α-MSH stay critically low with HRV collapsed, transition to Phenotype D.	Durable recovery, or a clear C→D re-phenotyping decision.

> **One without the other plateaus.** The signature failure of this phenotype is treating mitochondria or immunity alone. Run both arms together; the stepwise recovery smooths as each reinforces the other.

08 · AT A GLANCE

Master summary

Agent	Lever	Mechanism (one line)	Dosing	Ev.
Thymosin α-1	immune retrain	Restores T-cell/NK function; Th1; T-reg set-point	~1.6 mg SubQ 2×/wk	C
LDN	immune/microglia	OGF rebound modulation; TLR4 quieting	1.5→4.5 mg qHS	B
Sterols/sterolins	Th1/Th2 balance	Modulates (not boosts) T-cell/NK; damps Th2	20/0.2 mg 3×/d	C
AHCC / β-glucan	NK/innate	NK activity; innate training; antiviral	AHCC 1–3 g/d	C
Antivirals (Rx)	viral suppression	Suppress EBV/HHV-6/CMV reactivation	per protocol	B
Lactoferrin/ monolaurin	antiviral	Disrupt enveloped virus; NK support	see text	C
Mito stack (B)	engine	CoQ10, NAD+, carnitine, B-cplx, Mg, NAC	see Phenotype B	B–C
P5P / one-carbon	cofactor	Replaces viral PLP depletion; one-carbon	P5P + methylfolate/B12	C
Vitamin D / zinc	antiviral immunity	Regulatory & antiviral immune support	D to 40–60 ng/mL; Zn 15–30 mg	B
Thymosin β-4	repair (later)	Tissue repair / immune modulation	compounded	D

09 · EVIDENCE, SAFETY & SOURCING

Honest framing

The immune and antiviral mechanisms are well grounded; their application to CDR2-Immune biotoxin illness is mechanistically reasoned. LDN (adjacent indications), antivirals (in defined viral contexts), and vitamin D/zinc reach good human data; thymosin α-1, plant sterols/sterolins, AHCC, and the natural antivirals rest more on mechanistic and adjacent-population support.

- **Monitor** CD3/CD4/NK recovery, GDF15/FGF21 trend, viral markers, B6/vitamin D status, and HRV. The stepwise trajectory is expected; judge by direction over weeks.

- **Re-balance, do not over-boost** — in a dysregulated immune system, indiscriminate stimulation can flare; favor modulators (TA1, sterols, LDN) and watch for autoimmune signals.
- **Antiviral & peptide governance** — antivirals specialist-directed with monitoring; TA1/TB-4 off-label and compounded from documented sources.
- **Run both arms** — the mitochondrial stack runs concurrently, not after, immune work.

*This document supports clinician decision-making and education within the Beyond Mold CDR/ISRmt framework. It is a clinical synthesis, not a guideline: it is not individualized medical advice, does not establish a standard of care, and does not replace prescriber judgement, informed consent, or appropriate monitoring for the individual patient. Many agents are used off-label and several peptides are compounded; source from reputable compounding pharmacies with potency and sterility documentation, and apply standard monitoring. Evidence grades are deliberately conservative: **A** RCT-level in this or a closely adjacent indication · **B** good human data, extrapolated here · **C** mechanistic + preclinical, limited human · **D** mechanistic / experimental only. Not a substitute for clinical judgement.*